EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial

Varun Jain, Colleen A McMullen, Joy I Kimbrough, Anna K Rockich, Daniel L Davenport, Gregory S Hawk, Barbara S Nikolajczyk, Philip A Kern, Simon J Fisher, Joshua P Steiner, William B Inabnet, Marlene E Starr

Journal of Surgical Research · 2026

DOI: 10.1016/j.jss.2026.01.004 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Surgical Research, 2026. Verfasst von Varun Jain und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of General, Endocrine, and Metabolic Surgery, Department of Surgery, University of Kentucky, Lexington, Kentucky. Hauptthemen laut MEDLINE: Obesity, Morbid, Bariatric Surgery, Preoperative Care, Incretins. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS, University of Kentucky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Bariatric surgery is the most effective treatment modality for individuals with morbid obesity, providing significant and durable weight loss and comorbidity resolution. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonists have shown promise as weight loss drugs, in addition to their use in the treatment of metabolic disorders. While multimodal weight management is the standard of care for individuals with morbid obesity, the benefit of antecedent GLP-1 therapy prior to bariatric surgery has not been well-studied. The objective of this study is to conduct a clinical trial testing the hypothesis that preoperative treatment with a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist enhances preoperative weight loss and decreases tissue inflammation, resulting in improved postoperative outcomes. MATERIALS AND METHODS: We designed a randomized controlled trial (RCT) comparing preoperative treatment with tirzepatide versus standard medical care prior to minimally invasive bariatric surgery with a target enrollment of 50 patients randomized 1:1. For 3 mo preoperatively, the control arm will receive standard care in the form of dietary and lifestyle modification recommendations, whereas the treatment arm will receive weekly tirzepatide, in addition to standard care. Blood will be collected at enrollment through 12-mo postoperatively and analyzed for inflammatory and metabolic markers. Tissues (adipose, stomach, and liver) will be collected intraoperatively for transcriptome profiling and histological assessment. RESULTS: This is an ongoing trial with no reportable results. CONCLUSION: Completion of this pilot RCT will provide data to support initiation of a multicenter RCT to determine therapeutic efficacy, and mechanisms of action, by which patients could benefit from preoperative treatment with tirzepatide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Obesity, MorbidBariatric SurgeryPreoperative CareIncretinsHumansTirzepatideWeight LossRandomized Controlled Trials as TopicFemaleTreatment OutcomeAdultMaleMiddle AgedGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Bariatric surgeryGLP-1ObesityTirzepatideWeight loss

Substanzen

TirzepatideIncretinsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Division of General, Endocrine, and Metabolic Surgery, Department of Surgery, University of Kentucky, Lexington, Kentucky.
  • Division of Research, Department of Surgery, University of Kentucky, Lexington, Kentucky.
  • Division of Healthcare Outcomes and Optimal Patient Services, Department of Surgery, University of Kentucky, Lexington, Kentucky.
  • Dr. Bing Zhang Department of Statistics, College of Arts and Sciences, University of Kentucky, Lexington, Kentucky.
  • Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky; Barnstable Brown Diabetes Center, University of Kentucky, Lexington, Kentucky.
  • Barnstable Brown Diabetes Center, University of Kentucky, Lexington, Kentucky; Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky.

Förderung

  • NIGMS NIH HHS
  • NIA NIH HHS
  • University of Kentucky
  • Office of The Provost

Zitieren

APA

Jain, V., McMullen, C. A., Kimbrough, J. I., Rockich, A. K., Davenport, D. L., Hawk, G. S., Nikolajczyk, B. S., Kern, P. A., Fisher, S. J., Steiner, J. P., Inabnet, W. B., & Starr, M. E. (2026). Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial. Journal of Surgical Research. https://doi.org/10.1016/j.jss.2026.01.004

Vancouver

Jain V, McMullen CA, Kimbrough JI, Rockich AK, Davenport DL, Hawk GS, et al. Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial. Journal of Surgical Research. 2026. doi:10.1016/j.jss.2026.01.004

BibTeX
@article{Jain2026,
  author = {Jain, Varun and McMullen, Colleen A and Kimbrough, Joy I and Rockich, Anna K and Davenport, Daniel L and Hawk, Gregory S and Nikolajczyk, Barbara S and Kern, Philip A and Fisher, Simon J and Steiner, Joshua P and Inabnet, William B and Starr, Marlene E},
  title = {Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial},
  journal = {Journal of Surgical Research},
  year = {2026},
  doi = {10.1016/j.jss.2026.01.004}
}
Kostenlos starten →